Viracta Therapeutics Inc
VIRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$388.7K
Close$
$-0.34
3598% downside
Current Fair Value
3598% downsideOvervalued by 3598% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $388,698.00 |
|---|---|
| Enterprise Value | $-12,738,302.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.32 |
| Beta | 0.28 |
| Outstanding Shares | 39,574,070 |
Return
| Return on Equity | 654.21% |
|---|---|
| Return on Assets | -197.14% |
| Return on Invested Capital | 713.47% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.05 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | -17.26 |
| Enterprise Value to EBIT | 0.27 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 11, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Viracta Therapeutics Inc
8 employees
CEO: Dayton Misfeldt Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral...